The clinical study was performed on 167 patients with a diagnosis of «Herpes simplex mouth» (B00.11) of ICD-10. All patients underwent a comprehensive survey in conjunction with dermatological department. Methods of examination of patients included clinical, sociological, radiological, functional, laboratory methods (smear epithelium by immunofluorescence, study the properties of the oral fluid, hematology research). Then all patients were assigned an identical complex treatment. As a local antiviral drug in the scheme
of complex treatment in the study group №1 used new pharmacological composition based on silicone glycerohydrogel (Silativit) with the addition of an antiviral and immunomodulatory Triazavirin ingredient; in the study group №2 – Dental Gel «Gerpenoks»; in the comparison group – 5% acyclovir ointment. Results. Clinical studies have shown the best results of treatment of patients with the use of a new pharmaceutical composition (reduction of periods of exacerbation of 1,4 times).
herpes simplex virus, complex treatment, new pharmaceutical composition